CART-19 Cells For MRD Positive CD19+ ALL

CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Inclusion Criteria:

• Signed written informed consent
• Aged between 1-60 years
• Patients with MRD positive CD19+ ALL
• Cardiac: Left ventricular ejection fraction ≥ 50%
• Adequate renal and hepatic function
• Performance status: Karnofsky ≥ 70%

Exclusion Criteria:

• Pregnant or lactating females.
• Any co-morbidity precluding the administration of CART-19 cells.